Cross-source identity
National Provider Identifier 1316123821 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|---|---|---|
| CMS NPPES |
| NPI 1316123821 |
| Registry identity — dermatologist, taxonomy 207N00000X |
| Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Medicare Part D | NPI 1316123821 | 27 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 4c80e98e… | Canonical resolved node · 3 identifier(s) · 0 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Skyrizi Pen(Risankizumab-Rzaa) | 24 | $491,643 |
| Dupixent Pen(Dupilumab) | 86 | $401,653 |
| Gamunex-C(Immune Globul G/Gly/Iga Avg 46) | 18 | $386,504 |
| Humira(Cf) Pen(Adalimumab) | 15 | $382,445 |
| Cosentyx Sensoready (2 Pens)(Secukinumab) | 18 | $261,055 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.